892 patents currently held
164 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
147
Ending by 2030
Dec 2026
Next term end
610
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2040 · High confidence
Also notable
Ends Apr 2029 · High confidence
Also notable
Ends Feb 2029 · High confidence
Also notable
Ends Jun 2034 · High confidence
Also notable
Ends Oct 2031 · High confidence
Also notable
Ends Oct 2029 · High confidence
Also notable
Ends Jun 2029 · High confidence
Also notable
Ends Mar 2032 · High confidence
Sheet Based Triply Periodic Minimal Surface Implants for Promoting Osseointegration and Methods for Producing Same
US 10,772,732
Cited by 52 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2040.
Droplet-based washing
US 8,613,889
Cited by 223 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Rationally-Designed Meganucleases with Altered Sequence Specificity and DNA-Binding Affinity
US 8,021,867
Cited by 170 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
RNA-Guided Gene Editing and Gene Regulation
US 10,704,060
Cited by 183 later US patents, top 1% of utility patents granted in 2020 in our data. Protection runs to 2034.
Plasmonic Assisted Systems and Methods for Interior Energy-Activation from an Exterior Source
US 8,376,013
Cited by 122 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Non-Regular Electrical Stimulation Patterns for Treating Neurological Disorders
US 9,744,363
Cited by 61 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Therapeutic Agents Comprising a GLP-1 Receptor Agonist and Elastin-Like Peptide
US 8,178,495
Cited by 118 later US patents, top 5% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Non-Invasive Energy Upconversion Methods and Systems for In-Situ Photobiomodulation
US 9,302,116
Cited by 203 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 5 fees due Nov 21 to 30, 2026 · next Nov 21
- 17 fees due Dec 2 to 30, 2026 · next Dec 2
- 13 fees due Jan 2 to 30, 2027 · next Jan 2
- 16 fees due Feb 1 to 27, 2027 · next Feb 1
- 13 fees due Mar 3 to 26, 2027 · next Mar 3
- 20 fees due Apr 3 to 30, 2027 · next Apr 3
- 12 fees due May 3 to 28, 2027 · next May 3
- 14 fees due Jun 1 to 29, 2027 · next Jun 1
- 14 fees due Jul 5 to 30, 2027 · next Jul 5
- 13 fees due Aug 6 to 27, 2027 · next Aug 6
- 15 fees due Sep 1 to 26, 2027 · next Sep 1
- 19 fees due Oct 2 to 30, 2027 · next Oct 2
- 9 fees due Nov 7 to 14, 2027 · next Nov 7
Recent changes
- Nov 2Assignment recorded on 1 record: Chilkoti, Ashutosh and 1 other to Duke University Recorded Nov 2, 2026, executed Aug 22, 2022. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76603, frame 502.
- Oct 30Assignment recorded on 1 record: Kraus, Virginia B. and 1 other to Duke University Recorded Oct 30, 2026, executed May 25, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76577, frame 83.
- 19 of the patents on this record were granted since Aug 23, 2026
- 28 terms have ended since Aug 23, 2026
- Nov 8 US 7,943,378 Tissue Engineering · term ended
- Oct 30 US 10,112,947 Substituted 6-Aminopurines for Targeting HSP90 · lapsed on the fee record
- Oct 28 US 8,869,447 Plant Growth and Imaging Devices and Related Methods and Computer Program Products · lapsed on the fee record
- Oct 18 US 8,377,674 Method for Producing Genetically-Modified Cells with Rationally-Designed Meganucleases with Altered Sequence Specificity · term ended
- Oct 18 US 8,304,222 Rationally-Designed Meganucleases with Altered Sequence Specificity and Heterodimer Formation · term ended
- Oct 18 US 8,163,514 Methods of Cleaving DNA with Rationally-Designed Meganucleases · term ended
- Oct 18 US 8,148,098 Methods of Cleaving DNA with Rationally-Designed Meganucleases · term ended
- Oct 18 US 8,143,016 Methods of Cleaving DNA with Rationally-Designed Meganucleases · term ended
- Oct 18 US 8,143,015 Methods of Cleaving DNA with Rationally-Designed Meganucleases · term ended
- Oct 18 US 8,133,697 Methods of Cleaving DNA with Rationally-Designed Meganucleases · term ended
- Oct 18 US 8,129,134 Methods of Cleaving DNA with Rationally-Designed Meganucleases · term ended
- Oct 18 US 8,124,369 Method of Cleaving DNA with Rationally-Designed Meganucleases · term ended
- Oct 18 US 8,119,381 Rationally-Designed Meganucleases with Altered Sequence Specificity and DNA-Binding Affinity · term ended
- Oct 18 US 8,119,361 Methods of Cleaving DNA with Rationally-Designed Meganucleases · term ended
- Oct 14 US 8,859,223 Compositions and Methods for Imaging Beta-Secretase Activity in Living Cells and Organisms · lapsed on the fee record
What they patent
The largest of its 610 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,075,922 | A Method of Co-Infusing a Deoxygenated Hemoglobin Containing Blood Substitute and Inorganic Nitrite In force · High confidence | In force | High confidence | |
| US 9,395,361 | Bead Incubation and Washing on a Droplet Actuator held by Advanced Liquid Logic, Inc. and Duke University In force · Medium confidence | In force | Medium confidence | |
| US 12,332,205 | Droplet-Based Surface Modification and Washing In force · High confidence | In force | High confidence | |
| US 7,439,014 | Droplet-Based Surface Modification and Washing In force · High confidence | In force | High confidence | |
| US 8,313,895 | Droplet-Based Surface Modification and Washing In force · High confidence | In force | High confidence | |
| US 8,729,018 | Therapeutic Agents Comprising Elastic Peptides In force · High confidence | In force | High confidence | |
| US 8,951,721 | Droplet-Based Surface Modification and Washing In force · Medium confidence | In force | Medium confidence | |
| US 9,328,154 | Therapeutic Agents Comprising Fusions of Growth Hormone and Elastic Peptides In force · High confidence | In force | High confidence | |
| US 9,458,218 | Therapeutic Agents Comprising Fusions of Insulin and Elastic Peptides In force · High confidence | In force | High confidence | |
| US 10,258,700 | Methods and Compositions for Delivering Active Agents with Enhanced Pharmacological Properties In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 892: 164 patents in force now held by others · 495 patents ended · 417 applications pending · 807 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.